secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-09-30T20:30:22+00:00
Accession:  0001104659-26-112356
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Outlook Therapeutics receives Nasdaq notice for bid price below $1.00, has until March 24, 2027 to regain compliance
--------------------------------------------------------------------------------

- Nasdaq notified Outlook Therapeutics on Sept 25, 2026 that its closing bid price was below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
- The company has 180 calendar days, until March 24, 2027, to regain compliance, requiring a closing bid price of at least $1.00 for 10 consecutive business days.
- Outlook may qualify for an additional 180-day period and could effect a reverse stock split to cure the deficiency.
- If not cured by the Compliance Date, Nasdaq will notify of delisting; the company may appeal to a hearings panel, but success is not assured.
- CFO Kevin Lundquist signed the Form 8-K dated September 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926112356/0001104659-26-112356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926112356/tm2626478d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-112356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer